文献速递胸部肿瘤

IA期腺癌肺段切除术与肺叶切除术的比较

Comparison of Segmentectomy and Lobectomy in Stage IA Adenocarcinomas.
PubMed 文献 · J Thorac Oncol · 2017-01-20

本研究基于监测、流行病学和最终结果(SEER)登记库的7989例病理IA期(T1b,>0至≤20 mm)肺腺癌患者,比较肺段切除术与肺叶切除术的生存。倾向评分匹配后,肺段切除术(n=552)与肺叶切除术(n=1085)的总生存(5年74.45% vs 76.67%,HR=1.09,95%CI 0.90-1.33)和肺癌特异性生存(5年83.89% vs 86.11%,HR=1.12,95%CI 0.86-1.46)无显著差异。作者认为肺段切除术的生存结局可能与肺叶切除术无差异,但需前瞻性随机试验进一步证实。

要点

  • 病理IA期(T1b,>0至≤20 mm)肺腺癌中,肺段切除术占7.1%(564例)。
  • 倾向评分匹配后,肺段切除术与肺叶切除术的总生存和肺癌特异性生存无显著差异。
  • 作者认为肺段切除术的生存结局可能与肺叶切除术无差异,需前瞻性随机试验进一步证实。

核心结论

  • 病理IA期(至少10 mm但不超过20 mm)肺腺癌患者接受肺段切除术的生存结局可能与部分接受肺叶切除术的患者无差异。
  • 这些结果应通过前瞻性随机试验进一步证实。

研究设计与样本

  • 回顾性队列研究,基于监测、流行病学和最终结果(SEER)登记库识别7989例病理IA期肺腺癌患者。
  • 采用逻辑回归生成术前特征的倾向评分,以平衡接受肺段切除术的选择偏倚。
  • 在倾向评分匹配组中比较肺段切除术与肺叶切除术的总生存和肺癌特异性生存。

主要发现

  • 全队列中,564例(7.1%)接受肺段切除术。
  • 全队列中,肺叶切除术的总生存和肺癌特异性生存优于肺段切除术(log-rank p < 0.01)。
  • 1:2倾向评分匹配后,肺段切除术(n=552)与肺叶切除术(n=1085)相比,总生存无显著差异(5年生存率74.45% vs 76.67%,HR=1.09,95%CI 0.90-1.33)。
  • 1:2倾向评分匹配后,肺段切除术(n=552)与肺叶切除术(n=1085)相比,肺癌特异性生存无显著差异(5年生存率83.89% vs 86.11%,HR=1.12,95%CI 0.86-1.46)。
  • 按性别、年龄、组织学亚型和评估淋巴结数量分层后,仍观察到相似的阴性结果。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 这些结果应通过前瞻性随机试验进一步证实。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Recent studies have suggested that segmentectomy may be an acceptable alternative treatment to lobectomy for surgical management of smaller lung adenocarcinomas. The objective of this study was to compare survival after lobectomy and segmentectomy among patients with pathological stage IA adenocarcinoma categorized as stage T1b (>0 to ≤20 mm) according to the new eighth edition of the TNM system. METHODS: In total, 7989 patients were identified from the Surveillance, Epidemiology, and End Results registry. Propensity scores generated from logistic regression on preoperative characteristics were used to balance the selection bias of undergoing segmentectomy. Overall and lung cancer-specific survival rates of patients undergoing segmentectomy and lobectomy were compared in propensity score-matched groups. RESULTS: Overall, 564 patients (7.1%) underwent segmentectomy. Lobectomy led to better overall and lung cancer-specific survival than segmentectomy for the entire cohort (log-rank p < 0.01). After 1:2 propensity score matching, segmentectomy (n = 552) was no longer associated with significantly worse overall survival (5-year survival = 74.45% versus 76.67%, hazard ratio = 1.09, 95% confidence interval: 0.90-1.33) or lung cancer-specific survival (5-year survival = 83.89% versus 86.11%, hazard ratio = 1.12, 95% confidence interval: 0.86-1.46) compared with lobectomy (n = 1085) after adjustment for age, sex, lymph node quantity, and histological subtype. Similar negative findings were identified when patients were stratified according to sex, age, histological subtype, and number of evaluated lymph nodes. CONCLUSIONS: Patients who underwent segmentectomy may have survival outcomes no different than those of some patients who received lobectomy for pathological stage IA adenocarcinomas at least 10 but no larger than 20 mm in size. These results should be further confirmed through prospective randomized trials.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Zhao ZR, Situ DR, Lau RWH, et al. Comparison of Segmentectomy and Lobectomy in Stage IA Adenocarcinomas. J Thorac Oncol. 2017. PMID: 28111235. doi:10.1016/j.jtho.2017.01.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。